Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry, including vaccines and productivity enhancers.
These biologically-based vaccines improve the health and welfare of pigs and poultry and reduce or eliminate the use of antibiotics, chemicals and drugs.
Within the Imugene product portfolio there are several vaccines at various stages in the development process, from products in the early research stage, through to others in the commercialisation and regulatory stage.
Imugene’s ‘production animal’ vaccines result in productivity and economic gains to the poultry and pig industries.
The patented Porcine and Fowl Adenoviral Vector Delivery Systems (PAV and FAV) are biological platform technologies and are the key to the commerciality of the Imugene range of vaccines. From these two systems, disease prevention vaccines and biologically based productivity enhancers are constructed.
Imugene's product portfolio targets a worldwide US$3 billion animal health market.
The Adenoviral Vector - The Biological Delivery System